Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Brief Summary: The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone.

A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine, Procedure: Radiotherapy | Intervention Type: BIOLOGICAL; Name: Immunotherapeutic GSK1572932A; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Cisplatin (CDDP); Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 4 | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 4 | Intervention Type: PROCEDURE; Name: Radiotherapy; Assigned to Arm(s): Cohort 4
B: Arm Label: Tecemotide (L-BLP25); Type: EXPERIMENTAL; Interventions: Biological: Tecemotide (L-BLP25), Drug: Single low dose cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Tecemotide (L-BLP25); Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Melanoma - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: RCC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: mCRPC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: NSCLC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: CRC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): Melanoma - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): RCC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): mCRPC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): NSCLC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): CRC - BMS-936558 (MDX-1106)
D: Arm Label: GSK1572932 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Control | Intervention Type: BIOLOGICAL; Name: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Assigned to Arm(s): GSK1572932 Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): Placebo Group

Answer: B